Litcius/Paper detail

Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment

Feifei Yang, Ting Hu, Jianquan Liu, Xiaoqian Yu, Liying Ma

2022European Journal of Medicinal Chemistry28 citationsDOIOpen Access PDF

Topics & Concepts

ImmunotherapyCancer immunotherapyCancerHistone deacetylaseHistoneImmune systemCancer researchImmunologyChemistryMedicineInternal medicineDNABiochemistryHistone Deacetylase Inhibitors ResearchProtein Degradation and InhibitorsMultiple Myeloma Research and Treatments
Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment | Litcius